Levicept

Levicept is a clinical-stage biotechnology company developing a once-monthly biologic treatment for osteoarthritis pain.

Its receptor fusion protein is designed to rebalance neurotrophin signalling in affected joints, potentially providing a non-opioid treatment option.

The company has completed a Phase II study involving more than 500 patients and has received acceptance of a US regulatory application supporting further development. The treatment remains investigational.